Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer

Trial Profile

Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms OCTOVA
  • Most Recent Events

    • 27 Sep 2018 Planned number of patients changed from 132 to 138.
    • 31 Aug 2018 Biomarkers information updated
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top